Breaking News, Financial News

Financial Report: Alexion

Solaris revenue up 67% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Alexion   1Q Revenues: $566.6 million (+67%) 1Q Earnings: $159.4 million (+94%) Comments: Solaris sales were $566.6 million, up 67%, which included $87.8 million in reimbursements of prior year shipments related to an agreement with the French government. Sales also include additions of new patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). R&D expenses were $191.5 million, up from $74.5 in 1Q13....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters